poster

Nonclinical Vehicle Formulations:HP-β-CD (Hydroxypropyl-Beta-Cyclodextrin) & The Risk of Hemolysis

Beta-cyclodextrin is a commonly used excipient in nonclinical vehicle formulations. In a recent study, vehicle formulated with 35% HP-β-CD resulted in hemolysis after a 5–10-minute
intravenous (IV) infusion in Sprague Dawley rats, as evidenced by red urine, increased serum bilirubin levels, and increased clinical pathology hemolysis scores.

During subcutaneous (SC) administration using 11.6% HP-β-CD, hemolysis did not occur, though histopathological changes at the injection site indicated local toxicity (edema, mixed inflammation, hemorrhage, and myofiber degeneration) 24 hours post dose.

Register to gain access to gated resources.

"*" indicates required fields

Country
Please only hit the submit button once.
I AGREE*
This field is for validation purposes and should be left unchanged.